Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: Multi-institutional experience

Journal of Clinical Oncology

Volumn 27, Issue 36, 2009, Pages 6237-6242

  Yan, Tristan D ^a   Deraco, Marcello ^a   Baratti, Dario ^a   Kusamura, Shigeki ^a   Elias, Dominique ^a   Glehen, Olivier ^a   Gilly, François N ^a   Levine, Edward A ^a   Shen, Perry ^a   Mohamed, Faheez ^a   Moran, Brendan J ^a   Morris, David L ^a   Chua, Terence C ^a   Piso, Pompiliu ^a   Sugarbaker, Paul H ^a  

^a ST GEORGE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; MITOMYCIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA; EPITHELIUM TUMOR; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; HYPERTHERMIC THERAPY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; MULTICENTER STUDY; PERITONEUM CANCER; PERITONEUM MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; INFUSION; MESOTHELIOMA; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PERITONEUM TUMOR; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; INFUSIONS, PARENTERAL; MALE; MESOTHELIOMA; MIDDLE AGED; PERITONEAL NEOPLASMS; PROGNOSIS; SURVIVAL RATE;

EID: 74949123203     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.9640     Document Type: Article

References (31)

1. Battifora H, McCaughey W: Tumors of the Serosal Membranes. Washington, DC, Armed Forces Institute of Pathology, 1994
2. Robinson BWS, Lake RA: Advances in malignant mesothelioma. N Engl J Med 353:1591-1603, 2005
3. Welch LS, Acherman YIZ, Haile E, et al: Asbestos and peritoneal mesothelioma among college-educated men. Int J Occup Environ Health 11:254-258, 2005
4. Price B, Ware A: Mesothelioma trends in the United States: An update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003. Am J Epidemiol 159:107-112, 2004
5. Spirtas R, Heineman EF, Bernstein L, et al: Malignant mesothelioma: Attributable risk of asbestos exposure. Occup Environ Med 51:804-811, 1994
6. Miller J, Wynn H: A malignant tumor arising from the endothelium of the peritoneum and producing a mucoid ascitic fluid. J Pathol Bacteriol 12:267, 1908
7. Chailleux E, Dabouis G, Pioche D, et al: Prognostic factors in diffuse malignant pleural mesothelioma: A study of 167 patients. Chest 93:159-162, 1988
8. Antman K, Shemin R, Ryan L, et al: Malignant mesothelioma: Prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. J Clin Oncol 6:147-153, 1988
9. Sridhar KS, Doria R, Raub WA Jr, et al: New strategies are needed in diffuse malignant mesothelioma. Cancer 70:2969-2979, 1992
10. Markman M, Kelsen D: Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 118:547-550, 1992
11. Yates DH, Corrin B, Stidolph PN, et al: Malignant mesothelioma in south east England: Clinicopathological experience of 272 cases. Thorax 52: 507-512, 1997
12. Neumann V, Muller KM, Fischer M: Peritoneal mesothelioma: Incidence and etiology. Pathologe 20:169-176, 1999
13. Eltabbakh GH, Piver MS, Hempling RE, et al: Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol 70:6-12, 1999
14. Sugarbaker PH, Welch LS, Mohamed F, et al: A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am 12:605-621, 2003
15. Yan TD, Brun E, Carlos A, et al: Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 14:41-49, 2007
16. Park BJ, Alexander HR, Libutti SK, et al: Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). Ann Surg Oncol 6:582-590, 1999
17. Feldman AL, Libutti SK, Pingpank JF, et al: Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 21:4560-4567, 2003
18. Nonaka D, Kusamura S, Baratti D, et al: Diffuse malignant mesothelioma of the peritoneum: A clinico-pathological study of 35 patients treated locoregionally at a single institution. Cancer 104:2181-2188, 2005
19. Deraco M, Nonaka D, Baratti D, et al: Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 13:229-237, 2006
20. Brigand C, Monneuse O, Mohamed F, et al: Malignant peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal chemohyperthermia: Results of a prospective study. Ann Surg Oncol 13:405-412, 2006
21. Loggie BW, Fleming RA, McQuellon RP, et al: Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg 67:999-1003, 2001
22. Yan TD, Yoo D, Sugarbaker P: Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol 32:948-953, 2006
23. Jacquet P, Sugarbaker PH: Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 82:359-374, 1996
24. Sugarbaker PH: Peritonectomy procedures. Ann Surg 221:29-42, 1995
25. Acherman YI, Welch LS, Bromley CM, et al: Clinical presentation of peritoneal mesothelioma. Tumori 89:269-273, 2003
26. Yan TD, Popa E, Brun E, et al: Sex difference in diffuse malignant peritoneal mesothelioma. Br J Surg 93:1536-1542, 2006
27. Sticca RP, Dach BW: Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am 12:689-701, 2003
28. Los G, Smals OA, van Vugt MJ, et al: A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity. Cancer Res 52:1252-1258, 1992
29. van de Vaart PJ, van der Vange N, Zoetmulder FA, et al: Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: Pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 34:148-154, 1998
30. Los G, Sminia P, Wondergem J, et al: Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats. Eur J Cancer 27:472-477, 1991
31. Simon GR, Verschraegen CF, Jänne PA, et al: Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: Final report of a phase II trial. J Clin Oncol 26:3567-3572, 2008